Resolution of Metabolic syndrome with reduction of visceral adipose tissue in a 47 year old patient with Type 2 Diabetes Mellitus
Resolution of Metabolic syndrome with reduction of visceral adipose tissue in a 47 year old patient with Type 2 Diabetes Mellitus
复制标题
DOI：
10.1016/j.dsx.2020.05.036
复制
发表时间：
2020-09-01
影响因子：
10
通讯作者：
Barnes, Jessica W.
中科院分区：
文献类型：
--
作者：
Dembrowski, Gerald C.;Barnes, Jessica W.
背景和目的：代谢综合征（MetS）被定义为包括内脏脂肪、胰岛素抵抗、高血压和血脂异常在内的一系列代谢异常，目前影响着美国超过三分之一的成年人，这突出了对现有治疗方法有效补充的需求。方法：我们报告了一例47岁的男性，有MetS病史和控制不良的2型糖尿病（T2D），他完成了20Lighter计划（20L），包括极低热量饮食（VLCD）。入组时BMI为32.7，HbA1c为9.6%，处方用药史包括莱诺普利、洛伐他汀、二甲双胍、格列美脲及西格列汀/二甲双胍联合用药。结果：开始20L后15周（项目完成后6周）体重明显减轻，内脏脂肪组织和HbA1C正常化，所有药物均停药。结论：虽然需要更长时间的随访，但本病例报告显示，一个包括相对较短时间营养完整的VLCD，然后逐渐恢复到适度饮食生活方式的综合方案，能够在临床上显著改善met和T2D控制不良的个体的健康和生活质量。2020年印度糖尿病。Elsevier Ltd.出版。版权所有。
Background and aims: Metabolic syndrome (MetS), defined as a cluster of metabolic abnormalities including visceral adiposity, insulin resistance, hypertension, and dyslipidemia, now affects more than a third of adults in the United States highlighting the need for effective complementary approaches to current treatments.Methods: We present a case report of a 47-year-old man with a history of MetS and poorly controlled Type 2 Diabetes Mellitus (T2D) who completed a 20Lighter program (20L) including a very low calorie diet (VLCD). At the time of enrollment his BMI was 32.7, HbA1c was 9.6%, and prescription medication history included lisinopril, lovastatin, and metformin, glimepiride, and combination sitagliptin/metformin.Results: Fifteen weeks after beginning 20L (6 weeks after program completion) marked reduction of weight, visceral adipose tissue and normalization of HbA1C was seen, and all medications were withdrawn.Conclusions: While longer follow-up is required, this case report shows that a comprehensive program including a relatively short period of nutritionally complete VLCD, followed by gradual return to moderate dietary lifestyle is capable of producing clinically significant improvements in health and quality of life in individuals with MetS and poorly controlled T2D. (c) 2020 Diabetes India. Published by Elsevier Ltd. All rights reserved.